Clinical Nephrology – Epidemiology – Clinical TrialsProteinuria as a modifiable risk factor for the progression of non-diabetic renal disease
Keywords
Cited by (0)
- 1
Other members of the Angiotensin-Converting Enzyme Inhibition and Progression of Renal Disease (AIPRD) Study Group include: R. Toto (Dallas, TX, USA), B.M. Brenner (Boston, MA, USA), A. Kamper (Copenhagen, Denmark), P. Zucchelli (Malpighi-Bologna, Italy), G. Becker (Melbourne, Australia), A. Himmelmann (Goteborg, Sweden), K. Bannister (Adelaide, Australia), P. Landais (Paris, France), A. Perna (Bergamo, Italy), S. Strandgaard (Copenhagen, Denmark), B.U. Ihle (Melbourne, Australia), L. Hannson (Goteborg, Sweden), J.P. Grünfeld (Paris, France), G.G. Van Essen (Groningen, The Netherlands), A.J. Apperloo (Groningen, The Netherlands), L. Oldrizzi (Verona, Italy), N.E. Madias (Boston, MA, USA), B. Delano (Brooklyn, NY, USA), T. Karim (Boston, MA, USA), and M. Reddy (Boston, MA, USA).